RCUS Arcus Biosciences, Inc.

NYSE
$24.97

Arcus Biosciences, Inc. (RCUS) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.93 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.1% since its last earnings release on August 5, 2026.

Arcus Biosciences Beat Consensus Estimates, Sees Revenue Below Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.93)
Rev est $15.6M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $27.64

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 6 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.